retatrutide gip glp-1 glucagon receptor agonist Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data GLP1-GIP receptor co-agonists: a promising

Sikirica, M

By Distribution Channel By distribution channel, drug stores & retail pharmacies accounted for a share of 44.68% in 2025 due to widespread geographic accessibility, established prescription dispensing networks, and pharmacist-led patient counseling that supports chronic therapy continuation

Therefore, both agonists and antagonists of the GIP receptor may be useful for the therapy of obesity (46)

The semaglutide versus tirzepatide comparison provides foundational context for understanding how dual agonism differs from single agonism, which then extends to understanding how triple agonism differs from dual

Long-Term Side Effects GLP-1 medications have been in use for almost 20 years, beginning with exenatide in 2005

Unlike older weight-loss drugs, retatrutide brings together three pathways in a single drug